- $145.19m
- $51.66m
- $138.90m
Brief: Quanterix Granted Breakthrough Device Designation From US FDA For Blood-Based p-Tau 217 Test For Alzheimer’s Disease
Quanterix Corp reports results for the quarter ended in December - Earnings Summary
Brief: Quanterix Q4 Net Income USD -12.409 Million
RCS - Germfree - Germfree Announces Appointment of 4 Board Members
Quanterix Corp expected to post a loss of 32 cents a share - Earnings Preview
Brief: Quanterix Announces First Collaborations With Five Health Networks To Aid The Diagnosis And Clinical Management Of Individuals With Alzheimer’S Disease
Quanterix Corp expected to post a loss of 32 cents a share - Earnings Preview
Brief: Quanterix Q3 Net Income USD -7.758 Million
Quanterix Corp expected to post a loss of 37 cents a share - Earnings Preview
Brief: Quanterix Launches High Accuracy p-Tau 217 Blood Biomarker Test To Aid Physician Diagnosis Of Alzheimer's Disease
Brief: Quanterix Announces New Agreement To Advance Blood Based Alzheimer's Disease Detection
Focus: Blood tests needed for widespread Alzheimer's diagnosis on the way
Brief: Millennium Management Llc Reports 5.3% Passive Stake In Quanterix Corporation
Brief: William P. Donnelly Appointed To Quanterix’S Board Of Directors
Brief: Quanterix Appoints Vandana Sriram As Chief Financial Officer
Quanterix Corp reports results for the quarter ended in June - Earnings Summary
Brief: Quanterix Q2 Net Income USD -6.064 Million
Quanterix Corp expected to post a loss of 38 cents a share - Earnings Preview
Brief: Quanterix Launches Lucentad Biomarker Blood Test To Aid Physician Diagnosis Of Alzheimer’S Disease